伐地那非治疗乳房功能障碍（ED）

阴部骨骼肌（ED）病患更举例来问道用作Vardenafil（南征地那非）透过治疗法对ED用药Sildenafil（西地那非）和Vardenafil（南征地那非）透过举例来问道更为实验，希望很难受益无偏见的结果。纽约-2006年9月20日，学术研究结果刊造出在《连续性篇文章》上，同时在埃及开罗召开的连续性医学国际协时会第十二届大时会上公布。这项学术研究非常与众不同，因为其资料来自一项关于PDE5（磷酸二脂底物5）诱发用药的必要对比诊断试验，该试验用作PDE5诱发用药来治疗法ED病患。整个学术研究经过除此以外使得针对每种用药的偏见约超越也就是问道。这是一项随机、随机对照、一个大和必要对比的诊断试验，用作西地那非和南征地那非治疗法患有ED、糖尿病、腹水和/或高血脂的成年人病患，更为了二者的治果。调查结果在数个会用的理论上同义标上南征地那非拿下了人口学意涵上的优势，在病患者满意度和举例来问道连续性的多个分析报告测试里面，南征地那非的表现并不比西地那非差。共有1，057名成年人必要参与了这项学术研究，他们首先连续四个小时注射一种用药，然后是一个小时时间的缓冲期，接着再连续四个小时注射另一种用药。病患者时会被问道这样的疑虑：“总的来问道，你比如说用作那种用药？”此外还有其他11个有关ED治疗法的疑虑。利用原订准则透过附加理论上分析报告在分析里面也被用作。资料推测38.9%的病患者举例来问道用作南征地那非，而34.5%的病患者愿意用作西地那非（26.6%的病患者无举例来问道连续性）。在阴部功能，满意度和总体满意度方面，南征地那非显著要强西地那非。在阴部时插入硬度，阴部维持时间，全程维持和阴部信心方面，南征地那非也有很低数目的阳连续性反应。这项学术研究的共同著者，连续性篇文章的主编Irwin Goldstein 解释问道：“该学术研究表明我们对PDE5诱发用药诊断差异的解读又行进了重要一步，赞同了南征地那非治疗法ED的。”现阶段有三种PDE5诱发用药可会用治疗法ED，它们分别是西地那非，他约达那非和南征地那非。根据学术研究者的问道法，所有这三种用药对一定范围的人群都表现造出理论上和选择连续性。来自必要对比的诊断实验资料（如本项学术研究）非常稀疏，然而这样的学术研究结果时会帮助诊断眼科医生对西地那非、南征地那非和他约达那非加以差异以并不需要最适合的用药仅供生殖病病患用作。背景知识：ED：阴部骨骼肌 Erectile dysfunction, ED是同义持续不用约超越或者维持阴部以满足。ED比只不过用的"阳萎"（Impotence）一词更确实，因为脑瘤一词十分相似一定歧连续性的贬义。ED可按其程度分为重、里面、重三度，脑瘤属于重度的ED。70年代后由于阴部生理反应和病理学学术研究的进展，人们认识到固然心理病症确实可以激起ED，但对大多数成年人来问道，ED与许多病症（腹水，糖尿病，心血管病症）、用药、外伤及手术后等有关，因为阴部机制是硬壳体上皮细胞间歇，血管壁扩充张，脑组织上升和静脉回流致使等非常简单血液动力学反复，在这一反复里面，任何骨骼肌的病症可以分为： 器质连续性ED 子宫颈腺癌缘故：仅限于任何有可能所致硬壳体血管壁脑组织下降的病症，如：血管壁粥样愈合，血管壁破损，血管壁狭窄，血管壁分流及心功能精神状态等，或有碍静脉回流闭合机制的白膜、硬壳窦内上皮细胞下降肇因的静脉断。 神经连续性缘故：里面枢、骨骼肌神经病症或破损皆可以所致阴部骨骼肌。 手术后与外伤：大血管手术后、腺癌根治术、腹时会阴肝腺癌根治术等手术后及骨盆骨折、腰椎压缩连续性骨折或骑跨伤，可以激起起有关的血管和神经破损，所致阴部骨骼肌。 生理反应连续性疾病、病症和长期注射某些用药也可以激起阴部骨骼肌。 本身病症：如硬结症（Peyronie's disease）、弯曲小头、严重背痛和包皮家养炎。 心理连续性ED 同义紧张、压力、焦虑症、焦虑和夫妻感情不和等精神心理病症所造成的阴部骨骼肌。 混合连续性ED 同义精神心理病症和器质连续性病症共同所致的阴部骨骼肌。此外，由于器质连续性ED未受益即时的治疗法病患抑郁症连带，怕失败，使ED治疗法更加偏向有用。欧美一组628同上ED病患病症界定的学术研究表明：心理连续性分之二39%。器质连续性为15.8%，混合连续性分之二45.2%。PDE5诱发剂PDE5是硬壳体里面上皮细胞细胞内第二信使NO-cGMP的分解底物。PDE5诱发剂很难上升cGMP的浓度，大幅提高硬壳体上皮细胞的收缩作用，并促进连续性刺激诱发的阴部反应。PDE5诱发剂类用药对ED治疗法具有最广泛的理论上和选择连续性。因此，该类用药被都是口服治疗法用药的参照准则。现阶段，该类用药仅限于三种：西地那非、南征地那非和他约达拉非。西地那非在1998年，南征地那非和他拉那非则是在2003年受益全球认证。在诊断用作以及诊断相异学术研究里面发现，PDE5诱发剂具有更佳的选择连续性和理论上。在基本上ED病患里面，诊断学术研究充分属实上述三种用药的理论上。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON -- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.编辑：bluelove

编辑： Zhu